Indegene reports strong Q2 FY26 revenue growth, approves strategic acquisitions

Indegene Limited reported 17.1% year-over-year revenue growth in INR terms to INR 8,042 million for the quarter ended September 30, 2025, and 12.4% growth in USD terms. The company also maintained a strong profitability profile, with an adjusted EBITDA margin of 18.2% and a PAT margin of 12.7%. For the first half of FY26, revenue from operations reached INR 15,650 million, a 14.8% YoY growth in INR terms.

The board of directors approved two strategic acquisitions: BioPharm, a US-based specialized marketing services agency with deep omnichannel expertise, and WARN & CO., a UK-based transformation consulting firm. These acquisitions are expected to strengthen Indegene's commercialization portfolio and business transformation consulting solutions. Indegene also approved an investment of up to €8.5 million in equity shares of its wholly-owned subsidiary, Indegene Ireland Limited, to support capex for business expansion.

Additionally, the company approved the allotment of shares under its ESOP 2020 and RSU 2020 Plans, and an amendment to its Anti-Sexual Harassment Policy. The financial results and auditor's report received an unmodified opinion, and the final dividend of INR 2 per share for FY25 was approved and paid.